BioNTech has been following with great concern the dramatic effects of the recent flood disaster in North Rhine-Westphalia and the Rhineland-Palatinate, Germany. The worst damage caused by the floods occurred among others not far from the Company’s headquarters in Mainz and its site in Idar-Oberstein.
BioNTech will donate 1,000,000 Euro to the German Alliance for Disaster Relief (Aktionsbündnis Katastrophenhilfe). By doing this the company would like to express its solidarity with and support the large number of people who have lost relatives, friends, homes and belongings.
Employees who are directly or indirectly affected should receive individual help from BioNTech. In addition, some BioNTech employees have expressed a wish to support the relief efforts on a voluntary basis. BioNTech would like to support this voluntary commitment by granting special leave.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.
BioNTech Contacts:
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
